Repligen Corporation (RGEN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Repligen Corporation (RGEN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

156.65

-1.79 (-1.13%)

At close: Jan 14, 2025, 3:59 PM

157.40

0.48%

Pre-market Jan 15, 2025, 05:54 AM EST

undefined% (undefined)

Bid	134.41
Market Cap	8.78B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.03
PE Ratio (ttm)	-5221.67
Forward PE	n/a
Analyst	Buy

Ask	172.64
Volume	494,714
Avg. Volume (20D)	578,845
Open	157.59
Previous Close	158.44
Day's Range	150.85 - 160.03
52-Week Range	113.50 - 211.13
Beta	undefined

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used i...

[Show more]

Industry Medical - Instruments & Supplies

Sector Healthcare

IPO Date Apr 29, 1986

Employees 1,783

Stock Exchange NASDAQ

Ticker Symbol RGEN

Website https://www.repligen.com

Analyst Forecast

According to 12 analyst ratings, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $185, which is an increase of 18.10% from the latest price.

Buy 66.67%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Repligen Corporation is scheduled to release its earnings on Feb 19, 2025, before market opens.
Analysts project revenue of $167.54M, reflecting a 7.57% YoY growth and earnings per share of 0.41, making a 24.24% increase YoY.

Why Price Moved

2 months ago · Source

+6.51%

Repligen shares are trading higher after the compa... Unlock content with Pro Subscription

5 months ago · Source

+16.37%

Repligen shares are trading higher. The company reported Q2 financial results.

News

23 hours ago · zacks.com

HRMY or RGEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two co...

1 month ago · zacks.com

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

2 months ago · seekingalpha.com

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier...

2 months ago · zacks.com

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.

2 months ago · benzinga.com

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.

2 months ago · zacks.com

Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates

Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago.

2 months ago · seekingalpha.com

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though inte...

2 months ago · zacks.com

Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.